The Staburo Managing Directors Josef Hoefler and Roland Stieger had the opportunity to join the AGAH Annual Meeting in April 2018, here in Munich. The conference focused on how to prevent or predict adverse drug reactions in early phase drug development. The major...

Staburo at the Biometric Colloquium 2018 in Frankfurt Staburo participated in the 64th Biometric Colloquium 2018 in Frankfurt, the annual meeting of the German Region of the International Biometric Society (IBS-DR). The conference was hosted by the faculty of medicine...

Tumour growth over time Longitudinal Data, Joint Models, and Surrogate Endpoints for Survival Analysis   Tumour burden has been shown to be associated with clinical outcomes in many oncological indications. To explore the impact of treatment on tumour growth over...

Biomarkers that help patients to choose the best treatment option, play a key role in drug development and precision medicine. The talk introduced the Virtual Twin Method by Foster et al. (2011). It is a multivariate, tree-based method that identifies patients who may...

The Engaged Database - TED With TED, users have access to a straightforward tool, based upon the European Medicines Agency (EMA) inspection database, which allows the comparison of the results of one or more audits, to a large number of audit results. The Engaged...

Welcome our teammates Hans and Bobby! We are very glad to welcome Hans Bauer and Bobby Reidy in our team. Hans and Bobby are both professionals with work experience and excellent education from first-class universities. They will support our clients in the areas of...

We are proud to announce that due to our remarkable growth in biostatistics and statistical programming, we were recently moving to a new office location. We will continue to offer the same costumer-friendly service from our new address at Aschauer Str. 26b in Munich,...

Staburo participated in the APF meeting on 24 November 2017 in Freiburg. This year, the APF was hosted by Roche. Speakers from pharmaceutical industry, academia and regulatory agencies discussed important topics on estimands, safety and Health Technlogy Assessment....

Big steps for Staburo in 2017 Last year was very successful for our company. Our major milestones were: Strategy workshop with Mission & Vision for 2022 Further internationalization with additional US, EU and UK projects New big pharma & new biomarker project...